StockNow
Log in
U.S. Markets

Abbott (ABT) reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

StockNow breaking-news AI analysis

Abbott reached agreements to resolve a portion of its preterm infant formula litigation, providing partial clarity on a significant legal overhang while maintaining its 2026 financial guidance.

1 stocks
ABTAbbott Laboratories$114.31Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Nvidia (NVDA) intends to begin small-batch shipments of a China-tailored LPU by the end of 2026, reports The Information citing sources

NVDAFed

Fed's Musalem (2028 voter) says strong growth and investment influencing bond market

U.S. Markets

Broadcom (AVGO) seeking more than USD 60bln in latest AI debt deal

AVGO